American Society of Gene and Cell Therapy 2017 Poster Presentation, Washington, D.C.
Genome Editing of Therapeutic CAR-T Cells Using A Novel Clo51-dCas9 (NextGEN™) CRISPR System
Xinxin Wang*, Xianghong Li*, Yening Tan, Min Tong, Joann Wu, Burton E. Barnett, Christopher Martin, Jenessa B. Smith, David L. Hermanson, Srinivas Rengarajan, Rebecca Codde, Julian Down, Eric M. Ostertag, Devon J. Shedlock

American Society of Gene and Cell Therapy 2017 Poster Presentation, Washington, D.C.
Gene Modification of Human T cells via piggyBac yields an anti-BCMA CARTyrin Cellular Product with Durable Efficacy in a TP53 KO MM model
David Hermanson, Burton Barnett, §Rohit Mathur, §Jin He, Xinxin Wang, Srinivas Rengarajan, Xianghong Li, Rebecca Codde, Yening Tan, Siddiq Abdul-Alim, Christopher Martin, Jenessa Smith, Min Tong, §Hans Lee, §Elisabet Manasanch, §Krina Patel, §Donna Weber, §Robert Orlowski, §Jing Yang, §Sattva Neelapu, Eric M. Ostertag, Devon J. Shedlock
1 Poseida Therapeutics, San Diego, CA 2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 3 MD ANDERSON CANCER CENTER, HOUSTON, TX 4The University of Texas MD Anderson Cancer Center, Houston, TX

American Association for Cancer Research 2017 Poster Presentation, Washington, D.C.
PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability
David L. Hermanson, PhD1*, Burton Earle Barnett, PhD1*, Srinivas Rengarajan, M.S.1*, Rebecca Codde, B.S.1*, Xinxin Wang, PhD1*, Yening Tan, M.S.1*, Christopher E. Martin, PhD1*, Jenessa Barbara Smith, PhD1*, Jin He, M.S.2, Rohit Mathur, PhD3*, Jing Yan, PhD2*, Sattva S. Neelapu, MD4, Eric M. Ostertag, MD, PhD1* and Devon J. Shedlock, PhD1*
1 Poseida Therapeutics, San Diego, CA 2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 3 MD ANDERSON CANCER CENTER, HOUSTON, TX 4The University of Texas MD Anderson Cancer Center, Houston, TX

American Society of Hematology 2016 Poster Presentation, San Diego, CA
A Novel BCMA-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
David L. Hermanson, PhD1*, Burton Earle Barnett, PhD1*, Srinivas Rengarajan, M.S.1*, Rebecca Codde, B.S.1*, Xinxin Wang, PhD1*, Yening Tan, M.S.1*, Christopher E. Martin, PhD1*, Jenessa Barbara Smith, PhD1*, Jin He, M.S.2, Rohit Mathur, PhD3*, Jing Yan, PhD2*, Sattva S. Neelapu, MD4, Eric M. Ostertag, MD, PhD1* and Devon J. Shedlock, PhD1*
1 Poseida Therapeutics, San Diego, CA 2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 3 MD ANDERSON CANCER CENTER, HOUSTON, TX 4The University of Texas MD Anderson Cancer Center, Houston, TX

American Society of Hematology 2016 Poster Presentation, San Diego, CA
piggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
Burton Earle Barnett, PhD*, David L. Hermanson, PhD*, Jenessa Barbara Smith, PhD*, Xinxin Wang, PhD*, Yening Tan, M.S.*, Christopher E. Martin, PhD*, Eric M. Ostertag, MD, PhD* and Devon J. Shedlock, PhD*

American Society of Hematology 2016 Poster Presentation, San Diego, CA
Development of Novel Non-Immunoglobulin Centyrin-Based CARs (CARTyrins) Targeting Human BCMA

Burton Earle Barnett, PhD*, Jenessa Barbara Smith, PhD*, Xinxin Wang, PhD*, David L. Hermanson, PhD*, Yening Tan, M.S.*, Eric M. Ostertag, MD, PhD* and Devon J. Shedlock, PhD*